A New Jersey Health System is leading three clinical trials with the goal of addressing and improving knowledge gaps in treatment and diagnosis of Alzheimer's disease, using amyloid PET imaging.
Along with Hackensack University Medical Center and the hospital's Center for Memory Loss and Brain Health, Hackensack Meridian Health will be leading the "Imaging Dementia -- Evidence for Amyloid Scanning (New IDEAS) Study" to assess the value of brain PET scans in diagnosing and managing Alzheimer's disease.
The medical center, meanwhile, is conducting two clinical trials. One will explore the potential of ATH-1017, an investigational medication for the treatment of mild to moderate Alzheimer's disease. The medication's safety and effectiveness will be studied for improving cognition in people with mild to moderate Alzheimer's disease.
The second trial is enrolling patients in the multicenter S-Citad clinical trial to study the safety and efficacy of escitalopram (Lexapro), an antidepressant, for treating agitation related to Alzheimer's disease. This study is sponsored by the U.S. National Institute on Aging.
